Two-Pronged attack: testing a powerful cancer drug duo

NCT ID NCT03195478

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested the safety and initial effectiveness of a combination of two immunotherapy drugs, nivolumab and ipilimumab, in Chinese patients with advanced solid tumors that had returned or spread after prior treatment. The main goals were to see what side effects occurred and to measure how many patients' tumors shrank or stopped growing. The study was small and early-stage, focusing on gathering data to see if the treatment was safe and showed promise for this specific patient group.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution

Guangzhou, Guangdong, 510080, China
Local Institution

Zhengzhou, Henan, 450052, China
Local Institution - 0001

Beijing, Beijing Municipality, 100142, China
Local Institution - 0004

Tianjin, Tianjin Municipality, 300222, China
Local Institution - 0011

Harbin, Heilongjiang, 155040, China
Local Institution - 0012

Guangzhou, Guangdong, 510655, China
Local Institution - 0013

Hangzhou, Zhejiang, 310009, China
Local Institution - 0015

Beijing, Beijing Municipality, 100021, China
Local Institution - 0016

Shanghai, Shanghai Municipality, 200025, China
Local Institution - 0018

Chengdu, Sichuan, 610041, China
Local Institution - 0020

Xi'an, Shan1xi, 710061, China
Local Institution - 0021

Wuhan, Hubei, 430030, China

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR